Yunkang Group (2325.HK) Stock Price

Yunkang Group Price

CLOSED
0.38
​
Market closed

Over the last 7 years Yunkang Group grew revenue by 1.8% annually, reaching 601.39 M CNY. Earnings per share have declined at 59.1% per year over the last 5 years. For Yunkang Group, the net margin of 0.5% is down versus 22.5% a few years ago. At today's price the dividend yield works out to roughly 5.22%.

Yunkang Group stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Yunkang Group business model & stock analysis

Yunkang Group Ltd. generates revenue through its three business segments. The Diagnosis Testing segment offers routine diagnostic testing, pathological examinations, infectious disease testing, genetic disease testing, and early cancer detection services to hospitals and non-medical clients, including financial institutions and insurance companies. The Hospital Management Business segment provides management services for community clinics, targeting healthcare facilities seeking operational support. The Research & Development Institution segment develops testing kits, supplying products to the company's internal testing services and potentially external partners. Revenue is derived from service contracts with hospitals, medical institutions, and commercial entities like financial and insurance firms. The Diagnosis Testing segment serves hospitals and non-medical clients such as financial institutions and insurance companies, with services including routine testing and early cancer detection. Hospital Management Business focuses on community clinics, offering management solutions to healthcare providers. Research & Development Institution creates testing kits used internally for diagnostic services, supporting the company's core operations. All segments target healthcare providers and commercial entities that require diagnostic solutions or clinic management support. Yunkang Group Ltd. primarily earns income from diagnostic testing services provided to hospitals and medical institutions, as well as management services for community clinics. Financial institutions and insurance companies are key clients for the Diagnosis Testing segment, utilizing services like infectious disease testing and genetic disease testing. The Research & Development Institution segment develops testing kits that support the company's internal testing operations, contributing to the overall service delivery model.

Frequently asked questions about Yunkang Group

7 analysts currently rate the Yunkang Group stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Yunkang Group to generate revenue of 794.17 M CNY and earnings per share of 0.01 CNY.

Converted at the current exchange rate, the Yunkang Group share trades at 0.05 EUR (0.38 CNY).

The expected revenue of Yunkang Group is 794.17 M CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Yunkang Group is 6.12 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Yunkang Group is currently 36.67. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Yunkang Group stock.

The price-to-sales ratio (P/S) of Yunkang Group is currently 0.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Yunkang Group stock.

The Eulerpool Quality Score for Yunkang Group is 3/10.

The ISIN of Yunkang Group is KYG9889T1067. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Yunkang Group is 2325.HK. The ticker symbol is used to trade Yunkang Group shares on the stock exchange.

Fair ValueTerminal
0.32 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Providers & Services
Number of shares
Employees
Revenue per Employee
311,438.63 CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CNY
Initial public offering
May 18, 2022
ISIN
KYG9889T1067
Cusip
G9889T106
Market capitalization
237.99 M CNYMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
38.92
P/S
P/Se
0.28
EV/EBIT
—
P/B Ratio
0.21
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
0.16 %
Last updated Nov 22, 2026, 3:45 AM

Yunkang Group Peer Group

Yunkang Group FIGI

2325:HK · BBG0177GDQ80